Compare Dover Corp (DOV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Novavax Inc — how do they compare? Dover Corp trades at $188.83 (market cap $25.45B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Dover Corp is far larger — about 14× Novavax Inc's market cap, and Dover Corp pays a 1.11% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Novavax Inc for 59 Days on average.
| DOV | NVAX | |
|---|---|---|
Market Cap | $25.45B | $1.82B |
Volume | 661,758 | 6,198,505 |
Sector | Industrials | Health |
52-Week High | $233.31 | $12.56 |
52-Week Low | $161.16 | $6.22 |
Typical Hold Time | 73 Days | 59 Days |
Enterprise Value | $26.95B | $1.39B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.96, showing modest daily gains of 0.36%. The stock maintains strong fundamentals with consistent earnings beats and a 67.86% analyst buy rating. Recent acquisitions and product launches demonstrate growth initiatives, while technical indicators signal near-term bearish pressure with support at $186. The company's 13.48% net margin and 14.98% ROE reflect operational efficiency.
DOV presents a compelling investment case with 28% upside to the $243.20 consensus target. Strong cash flow generation and dividend consistency support shareholder returns, though technical weakness and competitive industrial markets pose near-term risks. The upcoming Q3 2026 earnings report on September 30 will be crucial for confirming growth trajectory.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
